Pharmaceutical compositions comprising sepiapterin and uses thereof

A composition, the technology of mepterin, applied in the direction of drug combination, medical preparations containing active ingredients, medical preparations with non-active ingredients, etc., can solve problems such as nerve movement defects and reduce the formation of neurotransmitters

Pending Publication Date: 2020-08-04
PTC医疗MP公司
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Reduced Tyr synthesis and impaired Tyr and tryptophan hydroxylase activity lead to reduced neurotransmitter formation and subsequent neuromotor deficits

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions comprising sepiapterin and uses thereof
  • Pharmaceutical compositions comprising sepiapterin and uses thereof
  • Pharmaceutical compositions comprising sepiapterin and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0242] Example 1. Preparation of a pharmaceutical composition comprising mepterin and an antioxidant

[0243] The process related to the manufacture of a pharmaceutical composition comprising mepterin and less than 10% by total weight of an antioxidant is as follows:

[0244] 1. Put mepterin (0.34 kg), ascorbic acid (0.071 kg), microcrystalline cellulose (0.85 kg), croscarmellose sodium (0.14 kg) and colloidal silicon dioxide (0.085 kg) separately Screen through a 140 mesh sieve.

[0245] 2. Mix colloidal silicon dioxide with microcrystalline cellulose and pass the combined material through an 80 mesh screen.

[0246] 3. Put the sifted material from step 2 into the V-blender.

[0247] 4. Add the filtered croscarmellose, ascorbic acid and mepterin to the V-blender.

[0248] 5. Blend the contents of the V-blender for at least 10 minutes.

[0249] 6. Pass the mixture through a 140-mesh sieve.

[0250] 7. Store the mixture at -20°C.

Embodiment 2

[0251] Example 2. Preparation of Pharmaceutical Compositions Comprising Mepterin and Antioxidants in an Administration Vehicle

[0252] The composition prepared in Example 1 (180 mg / kg methotrexate) was added to an amount of Medisca® oral mix (2.5% (w / w) in water) sufficient to produce a metopterin concentration of 58.3 mg / mL glycerol, 27% (w / w) sucrose).

Embodiment 3

[0253] Embodiment 3. In vivo pharmacokinetic analysis of the pharmaceutical composition of the present invention

[0254] A total of 18 CD-1 mice were divided into 2 groups as summarized below. Each test article was evaluated at one dose level (180 mg / kg). All animals in each group received a single oral (PO) administration of one dose level of the test or control article. Doses (mg / kg) were calculated based on animal body weight. There were nine male mice in each group. Group 1 was given mepterin added to a citrate buffer solution consisting of 750 mg sodium metabisulfite, 639 mg sodium citrate, 2.69 g anhydrous citric acid, and 750 mg ascorbic acid in 300 mL sterile water . Then 1.5 grams of carboxymethylcellulose was added and stirred until dissolved. Mepterin (180 mg / kg) was added to the buffer to give a concentration of 27 mg / mL. Administer group 1 mice at a dose volume of 6.67 mL / kg. The preparation prepared in Example 2 was administered to the second group. Admi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
Login to view more

Abstract

The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and / or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.

Description

[0001] Background of the invention [0002] Primary tetrahydrobiopterin deficiency (PBD) results from deficiency of GTP cyclohydrolase I (GTP-CH), 6-pyruvyl-tetrahydropterin synthase (PTPS), or mepterin reductase (SR) (impaired tetrahydrobiopterin (BH4) biosynthesis), or by defects in BH4 recycling (pterin-4a-methanolamine dehydratase (PCD) or dihydropteridine reductase (DHPR) deficiency) . PBD accounts for 1-3% of all cases of hyperphenylalaninemia (HPA), while nearly all remaining cases are due to phenylalanine hydroxylase deficiency. [0003] BH4 is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase, fatty acid glyceryl ether oxygenase, and nitric oxide (NO) synthase. [0004] In PBD, impaired phenylalanine (Phe) to tyrosine (Tyr) hydroxylation leads to HPA. Reduced Tyr synthesis and impaired Tyr and tryptophan hydroxylase activity lead to reduced neurotransmitter formation and subsequent neuromotor deficits. [0005] Phenoty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K9/20
CPCA61K47/22A61K9/0095A61K47/38A61K31/519A61P3/00A61K9/1617A61P25/00A61K9/14A61K9/20A61K38/40
Inventor D.E.勒维
Owner PTC医疗MP公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap